<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237989</url>
  </required_header>
  <id_info>
    <org_study_id>FY2001</org_study_id>
    <nct_id>NCT02237989</nct_id>
  </id_info>
  <brief_title>Effects Of Native Collagen Type 2 Treatment</brief_title>
  <official_title>Effects Of Native Collagen Type 2 Treatment In Knee Osteoarthritis : A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eskisehir Osmangazi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eskisehir Osmangazi University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate symptomatic efficacy of native collagen type 2 on joint
      pain and function and its effects on urinary biological markers related to cartilage
      degeneration in patients with knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      39 patients diagnosed with knee osteoarthritis were separated into two groups. The 1st group
      includes 19 patients given 1500mg/day paracetamol, the 2nd group consists of 20 patients
      given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three
      months.Pretreatment and posttreatment Visual Analog Scale, Western Ontario and McMaster
      Universities Osteoarthritis Index (WOMAC), 20-m walking time and Short Form-36 (SF-36),
      Coll2-1, Coll2-1NO2 and Fibulin-3 levels in urine were compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change from baseline in pain at rest and during walking</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change from baseline in 20 meters walking time</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change from baseline in short form 36</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change from baseline in Coll2-1, Coll2-1NO2 and Fibulin-3 levels in urine</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>native collagen type 2 + paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>1500 mg</description>
    <arm_group_label>paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol+native collagen type 2</intervention_name>
    <description>paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
    <arm_group_label>native collagen type 2 + paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients aged 45-70 years with the diagnosis of primary knee OA
        according to the American College of Rheumatology (ACR) criteria, Kellgren Lawrence
        radiological stage II or III and knee pain -

        Exclusion Criteria:Patients with intraarticular injections or physical therapy within the
        last year, a previous lower extremity surgery, oral treatment with glucosamine chondroitin
        or other natural health products within the last month, serious concomitant systemic
        diseases, peripheral or central neurological disorder, hypersensitivity to paracetamol or
        se¬vere cardiac, renal, hepatic, hematologic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fulya Bakilan, Specialist</last_name>
    <role>Study Director</role>
    <affiliation>Yerkoy State Hospital</affiliation>
  </overall_official>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eskisehir Osmangazi University</investigator_affiliation>
    <investigator_full_name>Onur Armağan</investigator_full_name>
    <investigator_title>Onur Armagan, Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>knee osteoarthritis, native collagen type 2, paracetamol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

